Fusion Pharmaceuticals Investor Presentation Deck
August 2023, 33 slides
  1. Fusion Pharmaceuticals
  2. Related Decks
  3. Investor Presentation Decks
corporate presentation august | Fusion Pharmaceuticals
forward looking statements and legal disclaimers | Fusion Pharmaceuticals
resurgence | Fusion Pharmaceuticals
fusion is differentiated in the emerging space | Fusion Pharmaceuticals
unlocking the potential of in novel targets sty discovery | Fusion Pharmaceuticals
fusion is well positioned to bring tats to market from supply chain and alpha experience perspectives who | Fusion Pharmaceuticals
fusion oncology drug development | Fusion Pharmaceuticals
programs fusion growing and diverse portfolio | Fusion Pharmaceuticals
fusion phase actinium based program fusion acquired a phase trial with plan to develop i as a potential first to market activity of in patients who did not respond or progressed on or after agent at | Fusion Pharmaceuticals
multiple investigator sponsored studies support potential of | Fusion Pharmaceuticals
development strategy | Fusion Pharmaceuticals
a small molecule tat targeting receptor | Fusion Pharmaceuticals
development program are | Fusion Pharmaceuticals
tats as next generation | Fusion Pharmaceuticals
creating next gen replacing toxins with isotopes | Fusion Pharmaceuticals
targeting insulin like growth factor receptor | Fusion Pharmaceuticals
phase study design status | Fusion Pharmaceuticals
summary of interim results presented june | Fusion Pharmaceuticals
collaboration agreement with option to commercialize in solely funds unless fusion opts in | Fusion Pharmaceuticals
based tat provides enhanced tumor specificity | Fusion Pharmaceuticals
fusion strategy around combination therapies | Fusion Pharmaceuticals
and key milestones | Fusion Pharmaceuticals
scalable capacity to support multiple programs with tat platform as of balance sheet expected cash runway outstanding cash cash equivalents and investments cash to fund operations into basic common shares gen puna | Fusion Pharmaceuticals
future milestones by program | Fusion Pharmaceuticals
thank you | Fusion Pharmaceuticals
appendix | Fusion Pharmaceuticals
the cold antibody dose strategy be | Fusion Pharmaceuticals
plasma and platelet counts | Fusion Pharmaceuticals
phase trial preliminary safety summary | Fusion Pharmaceuticals
organ radiation absorbed doses | Fusion Pharmaceuticals
phase preliminary data | Fusion Pharmaceuticals
targeted alpha therapy tats as next generation antibody drug conjugates | Fusion Pharmaceuticals
| Fusion Pharmaceuticals
See More
Fusion Pharmaceuticals
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Tumor
Cancer
Solid tumor
Recent decks by Fusion Pharmaceuticals
Investor Presentation
January 2024
Investor Presentation
November 2023
IPO
June 2020
See all presentations by Fusion Pharmaceuticals (4 decks)
Related decks
TScan Therapeutics
IPO
July 2021
BioNTech
Investor Day
June 2022
Immix Biopharma
Investor Presentation
December 2023
Erasca
Investor Presentation
November 2023
Immix Biopharma
Investor Presentation
October 2023
BioAtla
Investor Presentation
January 2024
Enochian Biosciences
Results
August 2023
Immix Biopharma
Investor Presentation
September 2023
Recent decks by Fusion Pharmaceuticals
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
November 2023
IPO
June 2020
TScan Therapeutics
IPO
July 2021
BioNTech
Investor Day
June 2022
Immix Biopharma
Investor Presentation
December 2023
Erasca
Investor Presentation
November 2023
Immix Biopharma
Investor Presentation
October 2023
BioAtla
Investor Presentation
January 2024
Enochian Biosciences
Results
August 2023
Immix Biopharma
Investor Presentation
September 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights